|
BioPortfolio - Roche - New Overall Survival Study Results Confirm ...
Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin ( XELOX) is Comparable to. FOLFOX-4 for the First-Line Treatment of . ...
http://www.bioportfolio.com/news/New_Overall_Survival_Study_...
|
Biotechnology News Search
The results of a large Phase III randomised study in women with early breast cancer has shown that adding capecitabine (Xeloda) to a standard treatment ...
http://www.bioportfolio.co.uk/Biotechnology_News_from_Pharma...
|
The World Market for Cancer Therapeutics and Biotherapeutics, 3rd ...
Roche (coverage of Xeloda, Avastin, MabThera, Herceptin, Tarceva and pipeline drugs). * Sanofi-Aventis (coverage of Taxotere, Eloxatine and others) ...
http://www.bioportfolio.com/cgi-bin/acatalog/The_World_Marke...
|
Biotechnology News breast cancer Search
Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence ...
http://www.bioportfolio.co.uk/breast%20cancer-news.htm...
|
BioPortfolio - University of Nebraska Lincoln Center for ...
Capecitabine (Xeloda(R)) · Combination Therapy · Reduces Early Breast · Cancer Recurrence. 11th November, 2009. Finland, November 11 ...
http://www.bioportfolio.com/biocorporate/10622-University+of...
|
Biotechnology News FLUOROURACIL Search
Adding capecitabine (Xeloda) to standard adjuvant chemotherapy significantly reduced the risk of breast cancer recurrence, but the cost was a substantial ...
http://www.bioportfolio.co.uk/FLUOROURACIL-news.htm...
|
BioPortfolio News: - Capecitabine Added to Standard...
23 Sep 2009 ... Germany, show that adding capecitabine (Xeloda(R)) to anthracycline- and taxane-containing regimens prior to surgery (neoadjuvant ...
http://www.bioportfolio.com/news/Capecitabine_Added_to_Stand...
|